Low
₹
High
₹
| Previous Close | ₹118.25 |
|---|---|
| Day's Range | ₹118.25 - ₹120.00 |
| Open | ₹119.45 |
| 52 Week Range | ₹95.00 - ₹164.00 |
| Volume | 1,190 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 1.41 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.26 |
| Price/Earning (TTM) | 39.93 |
| TTM EPS (₹) | 2.99 |
| P/E Ratio | 35.42 |
| Book Value(₹) | 1.86 |
| PAT Margin (%) | 2.81 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 7.98 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 380.94 | 1260.08 |
| Expenses | N/A | N/A |
| PBT | 27.34 | 49.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 22.3 | 35.63 |
| Founded | 1989 |
|---|---|
| Managing Director | Purushotham Eaga |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,41,789.55 | 1,841.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,450.12 | 6,746.70 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,54,733.87 | 4,450.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,848.85 | 8,264.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,182.61 | 1,417.05 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,184.65 | 1,329.35 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,07,973.94 | 1,078.95 | 835.50 - 835.50 |
| Lupin Ltd. | 1,04,613.28 | 2,263.85 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,443.53 | 2,418.55 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 97,382.77 | 993.00 | 903.00 - 903.00 |
No Records Found
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Smruthi Organics has informed that the Company has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Europe for its product Amlodipine Besilate. The CEP certifies that the quality of the substance complies with the requirements of the European Pharmacopoeia and enables the Company to supply this product to pharmaceutical manufacturers in European markets and other regions that recognize the CEP certification. This milestone strengthens the Company’s regulatory portfolio and enhances opportunities to expand its presence in regulated markets.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Smruthi Orgnics has informed that the company has received an ‘Attestation of Inspection’ from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, following the inspection conducted at its flagship API manufacturing facility, Unit II, Solapur, Maharashtra from 27 August 2025 to 29 August 2025. The attestation confirms compliance with the applicable European Good Manufacturing Practice (EU GMP) requirements under the CEP framework in respect of Amlodipine Besilate. A detailed disclosure in this regard is enclosed.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Smruthi Organics Ltd. is ₹118.25 as of 2026-05-26.
The market capitalisation of Smruthi Organics Ltd. is ₹136.73 as of 2026-05-25.
The 1-year return of Smruthi Organics Ltd. is -17.55% as of 2025-05-23.
The P/E ratio of Smruthi Organics Ltd. is 35.42 as of 2026-05-26.
The 52-week high and low of Smruthi Organics Ltd. are ₹164.00 and ₹95.00, respectively, as of 2026-05-26.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.